نتایج جستجو برای: دیگوکسین digoxin

تعداد نتایج: 3205  

Journal: :Medicina-lithuania 2023

Background: Atrial flutter is an infrequent yet potentially fatal arrhythmia. Digoxin the preferred first-line treatment for fetal atrial due to its efficacy and favorable safety profile. The optimal digoxin serum target level neonatal management remains uncertain, with standard ranging from 1.0 2.0 ng/mL potential toxicity concerns above this threshold. Case Presentation: We present a case of ...

2004

P-glycoprotein (P-gp) is an ATP-dependent efflux membrane transporter involved in many drug pharmacokinetics in humans. Decreasing its expression could enhance the bioavailability of substrates as digoxin. We have recently found that human recombinant interleukin-2 (rIL2) in vivo decreases P-gp expression in intestine and brain of mice and modifies oral digoxin pharmacokinetics. The aim of the ...

Journal: :JACC. Heart failure 2016
Nish Patel Christine Ju Conrad Macon Udho Thadani Phillip J Schulte Adrian F Hernandez Deepak L Bhatt Javed Butler Clyde W Yancy Gregg C Fonarow

OBJECTIVES The aim of this study was to assess temporal trends and factors associated with digoxin use at discharge among patients admitted with heart failure (HF). BACKGROUND Digoxin has class IIa recommendations for treating HF with reduced ejection fraction (HFrEF) in the United States. Digoxin use, temporal trends, and clinical characteristics of HF patients in current clinical practice i...

Journal: :Circulation research 1973
R E Goldstein S C Penzotti K S Kuehl K H Prindle C A Hall E O Titus S E Epstein

To clarify the suppressant action of diphenylhydantoin (DPH) on digitalis-induced arrhythmias we studied effects of DPH and digoxin, alone and in combination, on contractile force, sodium-potassium adenosinetriphosphatase (Na + -K ATPase) activity, and potassium (K) balance in dog hearts perfused with Krebs-Ringer's solution. Neither control perfusion nor DPH alone (3 X 10"M) altered Na + -K AT...

2017
Min-Huey Chung Yi-Wen Wang Yung-Lung Chang Shih-Ming Huang Wei-Shiang Lin

Heart failure (HF) is the leading cause of death in the world and digoxin remains one of the oldest therapies for HF. However, its safety and efficacy have been controversial since its initial use and there is uncertainty about its long-term efficacy and safety. Recently, the repositioning of cardiac glycosides is to function in anti-tumor activity via multiple working pathways. It is interesti...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2016
Helen J Renaud Curtis D Klaassen Iván L Csanaky

There is wide variation in how patients respond to therapeutics. Factors that contribute to pharmacokinetic variations include disease, genetics, drugs, age, and diet. The purpose of this study was to determine the effect of calorie restriction on the expression of Abcb1a in the intestine and whether calorie restriction can alter the absorption of an Abcb1a substrate (i.e., digoxin) in mice. Te...

Journal: :Journal of clinical pharmacy and therapeutics 2005
W L G Kroese A J Avery B S P Savelyich N S Brown H Schers R Howard J Hippisley-Cox P Horsfield

BACKGROUND This study was carried out as part of a European Union funded project (PharmDIS-e+), to develop and evaluate software aimed at assisting physicians with drug dosing. A drug that causes particular problems with drug dosing in primary care is digoxin because of its narrow therapeutic range and low therapeutic index. OBJECTIVES To determine (i) accuracy of the PharmDIS-e+ software for...

Journal: :Archives of internal medicine 2006
Jerry L Bauman Robert J DiDomenico Marlos Viana Melissa Fitch

BACKGROUND The therapeutic range for digoxin in heart failure has recently changed to become lower and narrower, and the new range is associated with improved mortality. However, dosing methods have not been modified to reflect this change. In this study, we sought to develop a new method to determine the initial dose of digoxin in patients with heart failure. METHODS Over a 6-month period, m...

2012
James H Flory Bonnie Ky Kevin Haynes Steve M Brunelli Jeffrey Munson Christopher Rowan Brian L Strom Sean Hennessy

OBJECTIVES This study aims to assess whether digoxin has a different effect on mortality risk for women than it does for men in patients with heart failure (HF). DESIGN This study uses the UK-based The Health Information Network population database in a cohort study of the impact of digoxin exposure on mortality for men and women who carry the diagnosis of HF. Digoxin exposure was assessed ba...

Journal: :The Journal of pharmacology and experimental therapeutics 2006
Justine L Lam Sarah B Shugarts Hideaki Okochi Leslie Z Benet

Because rifampin (RIF) induces hepatic enzymes and inhibits uptake transporters, dosing a drug that is a dual substrate of enzymes and uptake transporters on the final day of an inducing regimen should exhibit less inductive effect than dosing on the following day in the absence of RIF, since RIF decreases drug uptake into liver. In vitro and in vivo rat studies were conducted using digoxin as ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید